Background Although abnormal uterine bleeding is a known adverse effect of anticoagulant
drugs, true rates have not been widely studied. Society-backed recommendations and …

Bleeding is a well-recognized side effect of anticoagulant therapy, which is used to treat
venous thromboembolism (VTE) in individuals of all ages, including those of female sex …

Abnormal uterine bleeding (AUB) is a common complication of anticoagulant therapy in
premenopausal women affected with acute venous thromboembolism. AUB impacts quality …

Up to two-thirds of menstruating women experience abnormal uterine bleeding (AUB) when
treated with oral anticoagulants. However, the true prevalence of AUB for specific agents …

Introduction Little is known about the clinical characteristics of women at increased risk for
abnormal uterine bleeding (UB) during anticoagulation for venous thromboembolism (VTE) …

Background Antithrombotic therapies are associated with an increased bleeding risk.
Abnormal uterine bleeding data have been reported in clinical trials of patients with venous …

Results We identified 80,967 OA users and 4,245,694 nonusers. OA nonusers were younger
(mean age 44.1 vs 69.3 years) at the time of their UB diagnosis and more likely utilized …

Preliminary data and clinical experience have suggested an increased risk of abnormal
uterine bleeding (AUB) in women of reproductive age treated with anticoagulants, but solid …

Background Although heavy menstrual bleeding (HMB) is a known complication of
anticoagulant therapy, rates of HMB in users of the direct oral anticoagulants (OACs) …

Background Observational data and results from post-hoc analyses in clinical trials suggest
that direct oral factor Xa inhibitors might increase menstrual bleeding intensity in women of …